Agree that 50% doesn't sound like a high bar...but we are desperate for something to improve a very difficult situation. Hopefully we achieve much higher.
You could be right..it is so difficult to predict what the market will do under various circumstances. We've seen very very little, no and even negative movement within the market when we have excellent news. So if a simple straight-line thinking prevails, I think we could see some decline.
However, if the market "thinks" a bit more deeply, it will realise that we still have a tremendous need for therapies:
- Antivaxers won't take it
- Significant % of general population will wait due to safety concerns--a PR nightmare.
- % of vaccinated won't be protected (ineffective, timing, etc)
- Demand likely to outstrip supply until capacity ramps up.
- Virus mutation
- Many COVID survivors need help recovering, including "long-haulers."
- Leronlimab has mind-boggling potential to treat a host of maladies including HIV, Parkinsons, MS, NASH, ED, Male Pattern Baldness (OK, I made the last two up but who knows...?)
I agree that it will be better to get Leronlimab EUA before vaccine, if possible, but I don't think it will sink the CYDY ship.
Some of the material I find most encouraging is Bruce Patterson interview w/Dr. Yo; Bruce Patterson interview w/Dr. Been and Yo, Bruce Patterson's TEDx talk (test panel for targeted therapies.)
These are exciting times...any may CYDY breakthroughs be an integral part of a bio-renaissance!